CAL02
Revolutionizing Infectious Diseases TreatmentCAL02, a first-in-class, broad-spectrum, anti-virulence agent under development for the treatment of severe community-acquired bacterial pneumonia (SCABP)
Our innovative therapeutic approach uses proprietary engineered liposomes to capture and neutralize harmful toxins produced by a broad range of virulent bacteria. This breakthrough technology works against both Gram-positive and Gram-negative bacteria that cause life-threatening infections, including severe pneumonia.
Transforming Patient Care
Clinical results demonstrate CAL02’s potential to revolutionize treatment standards while dramatically reducing recovery time and healthcare costs for millions of critically ill patients worldwide*.
* CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Laterre PF et al. Lancet Infect Dis. 2019; 19(6):620-630.
Regulatory Recognition & Progress
- FDA Fast-Track designation
- Qualified Infectious Disease Product (QIDP) status
- Global Phase 2b clinical study currently underway
Worldwide out-licensing agreement signed with Eagle Pharmaceuticals for the commercial rights to CAL02